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Ex vivo and in vitro studies have revealed the remarkable amyloid
inhibitory potency and specificity of iododiflunisal in relation
to transthyretin [Almeida, Macedo, Cardoso, Alves, Valencia,
Arsequell, Planas and Saraiva (2004) Biochem. J. 381, 351–356],
a protein implicated in familial amyloidotic polyneuropathy. In
the present paper, the crystal structure of transthyretin complexed
with this diflunisal derivative is reported, which enables a detailed
analysis of the protein–ligand interactions. Iododiflunisal binds
very deep in the hormone-binding channel. The iodine substituent
is tightly anchored into a pocket of the binding site and the fluo-
rine atoms provide extra hydrophobic contacts with the protein.
The carboxylate substituent is involved in an electrostatic inter-
action with the Nζ of a lysine residue. Moreover, ligand-induced
conformational alterations in the side chain of some residues result
in the formation of new intersubunit hydrogen bonds. All these
new interactions, induced by iododiflunisal, increase the stability
of the tetramer impairing the formation of amyloid fibrils. The
crystal structure of this complex opens perspectives for the design
of more specific and effective drugs for familial amyloidotic poly-
neuropathy patients.
Key words: amyloid fibril, amyloid inhibitor, complex crystal
structure, familial amyloidotic polyneuropathy, iododiflunisal,
transthyretin.
INTRODUCTION
TTR (transthyretin) transports approx. 20% of the T4 (thyroxine)
circulating in the plasma and is the main carrier of retinol, by
forming a complex with the retinol-binding protein [1]. Early
X-ray crystallography studies by Blake et al. [2] revealed that the
protein is a tetramer with identical subunits. Each subunit, the mo-
nomer, has a β-sandwich structure composed of two four-stran-
ded β-sheets (DAGH and CBEF) and a small helical region
between strands E and F. The four monomers assemble, forming
a central channel where two T4 molecules can be accommodated
simultaneously.
TTR is one of the human proteins that forms amyloid fibrils
associated with diseases such as familial amyloid cardiomyo-
pathy, senile systemic amyloidosis and familial amyloidotic poly-
neuropathy. The fibrils have a characteristic green birefringence
when observed under polarized light after Congo Red staining.
Furthermore, their X-ray diffraction patterns always disclose a
β-sheet structure organized with the sheets parallel to the fibril
axis and the β-strands perpendicular to it [3].
Several models for TTR amyloid fibrils have been described in
the literature. Although some researchers proposed that the TTR
tetramers would associate through disulphide bridges [4], others
proposed that dimers [5,6] and monomers [7] were the building
blocks. Redondo et al. [8] addressed this question using two syn-
thetic TTR variants in which the four monomers, in one case,
and two dimers, in a different variant, were linked by disulphide
bonds. ‘In vitro’ fibrillogenesis assays led to the conclusion that
these mutants were unable to polymerize, even at low pH.
However, on the reduction of the disulphide bonds with 2-mer-
captoethanol, these variants were capable of assembling into
fibrils.
It is now accepted that most probably the dissociation of the
TTR tetramer into monomers occurs before fibril formation. An
assembly mechanism, where two edge strands (C and D) are
displaced and the fibril is formed by end-to-end alignment of the
non-native monomers, was proposed based on EPR measurements
of various spin-labelled single-cysteine mutants of TTR [9].
Interestingly, the crystal structure of the highly amyloidogenic
L55P-TTR variant revealed a structural change of the edge strand
D, leading to a long loop between strands C and E [10]. Further-
more, the displacement of strand D is in agreement with the ob-
servation that the protein’s sulphur-containing amino acids be-
came oxidized on fibrillization [11], since these residues are in
the vicinity of the displaced strand and probably become more
accessible to the solvent.
Since TTR amyloid fibril formation requires the dissociation
of the tetramer into monomeric species before aggregation, small
molecules capable of binding in the T4 binding channel, which
runs through the centre of the molecule and induces the form-
ation of new intersubunit interactions, should stabilize the native
state of the protein and thereby prevent the early steps of amyloid
fibril formation. In fact, several compounds have already been
shown to have an inhibitory effect on amyloid fibril formation
in vitro, due to binding in the TTR channel [12]. Among the
most promising inhibitors are NSAIDs (non-steroidal anti-inflam-
matory drugs) such as diclofenac, diflunisal and flufenamic acid
[13]. Other proposed approaches for the stabilization of TTR’s
native structure include the sulphonation of the single cysteine
residue, situated at position 10 of the polypeptide chain, by the
addition of sulphite [14]. It was suggested that the sulphonated
cysteine residue forms a new hydrogen bond with the main chain
nitrogen of Gly57, positioned in the β-strand D, contributing to
the inhibition of tetrameric dissociation [15].
Abbreviations used: NSAID, non-steroidal anti-inflammatory drug; r.m.s., root mean square; T4, thyroxine; TTR, transthyretin.
1 To whom correspondence should be addressed, at Instituto de Biologia Molecular e Celular (email amdamas@ibmc.up.pt).
The refined co-ordinates and the structure factors of the transthyretin–iododiflunisal complex have been deposited in the RCSB Protein Data Bank (PDB
ID: 1Y1D).
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Figure 1 Chemical structure of iododiflunisal, a difluorophenyl derivative
of iodinated salicylic acid
In the course of a screening programme, we have identified
an iodinated substance of a difluorophenyl derivative of salicylic
acid, which we have termed iododiflunisal (2′,4′-difluoro-4-hy-
droxy-5-iodo-[1,1′-biphenyl]-3-carboxylic acid) (Figure 1). The
compound shows unique features when compared with other
proposed TTR stabilizers like diflunisal, flufenamic acid and
diclofenac. Among these well-studied drugs, iododiflunisal is the
only one that shows an evident stabilizing effect on TTR tetramers
in plasma under semi-denaturing conditions [16]. Moreover, the
biological action of iododiflunisal in plasma seems to be very
selective owing to the fact that it preferentially displaces T4 from
TTR over albumin and T4 binding globulin. In addition, it prevents
the oligomerization of TTR Y78F, as evaluated by transmission
electron microscopy [16]; TTR Y78F is a mutant protein that
in solution reveals epitopes similar to those present in fibrils,
as assessed by monoclonal antibodies specific to TTR amyloid
fibrils, and has high propensity to form amyloid fibrils [17].
To identify the critical molecular features and understand the
molecular interactions that give rise to iododiflunisal amyloid in-
hibitory properties, elucidation of the three-dimensional structure
of the TTR–iododiflunisal complex at the atomic level was at-
tempted. Accordingly, in the present study, we report the crystal
structure of TTR complexed with iododiflunisal and identify the
key interactions between the protein and the drug, as well as
the newly obtained interactions between the monomers in the pro-
tein tetramer.
EXPERIMENTAL
Co-crystallization of the TTR–iododiflunisal complex
Recombinant TTR was produced in a bacterial expression system
using Escherichia coli BL21 [18] and purified as described else-
where [19]. Iododiflunisal was identified in the course of a screen-
ing program for the synthesis of TTR amyloid inhibitors per-
formed at CSIC (IIQAB, Barcelona, Spain) and at the University
of Oviedo (Oviedo, Asturias, Spain). Iododiflunisal was prepared
by electrophilic aromatic iodination of diflunisal and used after
HPLC purification and characterization by NMR and MS.
The protein (12.6 mg · ml−1) was incubated with iododiflu-
nisal [molar ratio: iododiflunisal (99.9% purity)/TTR = 10] in
0.165 M sodium citrate buffer (pH 7.0) containing 0.25% (v/v)
1,2,3-heptanetriol for 2 days at 4 ◦C. Crystals of the complex,
suitable for X-ray diffraction, were obtained by hanging-drop
vapour-diffusion techniques at 14 ◦C. Crystals belonging to space
group P21212 were grown within 1 week by mixing 3 µl of
the TTR–iododiflunisal complex with 3 µl of reservoir solution
containing 200 mM citrate buffer, 2.4 M ammonium sulphate and
6% (v/v) glycerol (pH 5.0). Crystals with maximal dimensions
of 0.5 × 0.3 × 0.1 mm3 were transferred to reservoir solutions
containing increasing concentrations of glycerol (10–20%) and
flash frozen in liquid nitrogen.
Data collection, processing and refinement
The X-ray diffraction data were collected using synchrotron radi-
ation on ID14-3 beam line at the ESRF (European Synchrotron
Radiation Facility, Grenoble Cedex, France).
Crystals were diffracted to a maximum resolution of 1.7 Å
(10−10 m). Determination of the crystal orientation and integration
was performed with MOSFLM [20], and the scaling and merging
of the reflections were performed using programs SCALA and
TRUNCATE [21].
The structure of the TTR complex was determined by molecular
replacement with AMoRe [22] using T119M-TTR as the starting
model (PDB accession no. 1F86; [23]), after the removal of
water molecules and mutation of residue 119 to alanine. Several
cycles of refinement were performed with the program CNS [24],
alternating with manual model building using the program Turbo-
FRODO [25] in an SGI graphic workstation, until the protein
model was completely fitted to the Fourier map. The refinement
was monitored using Rfree, the cross-validation R-factor, calculated
from a set of 5% of the reflections, which was kept aside from
the initial refinement. The refinement was obtained using
SHELXL [26]. Water molecules were added at the position of
positive peaks (>3σ ) on the difference Fourier maps where good
hydrogen bond geometry existed. The position of iododiflunisal
could be clearly identified in the Fo–Fc electron density map
(where Fo and Fc are the observed and calculated structure factor
amplitudes respectively) and the occupancies of the ligand atoms
were refined using SHELXL. The last refinement cycles of the
TTR–iododiflunisal model were performed with REFMAC5 [27]
from the CCP4 suite [21]. The stereochemistry of the refined
model was checked with PROCHECK [28] and all the residues
included in the protein model were in the allowed regions of the
Ramachandran plot. The Matthews coefficient is 2.18 Å · Da−1
for the crystals of the complex corresponding to a solvent content
of 43%.
Details of the crystallographic data collection and refinement
statistics are shown in Table 1.
RESULTS AND DISCUSSION
Overall structure of the TTR–iododiflunisal complex
The crystals belong to the orthorombic space group P21212, with
unit cell dimensions a = 43.3 Å, b = 85.8 Å and c = 64.9 Å. The
asymmetric unit contains two monomers, A and B, which form a
dimer. The two dimers that form the tetrameric protein are related
by a crystallographic 2-fold axis that runs along the hormone-
binding channel.
The final protein model includes residues 10–124 from mono-
mer A and 10–125 from monomer B, since the first nine re-
sidues from the N-terminal and last three (monomer A) and two
(monomer B) residues from the C-terminal could not be located
in the electron density map. A total of 169 water molecules were
identified and included in the final model. The side chains of
residues Asn27 (A), Arg34 (A), Glu72 (A), Ser115 (A) and Asn27 (B)
were refined in two well-defined conformations.
Monomers A and B are chemically identical and adopt gene-
rally similar conformations. The r.m.s. (root mean square)
deviation between main chain atom positions of all residues of
monomers A and B is 0.5 Å. The largest differences are observed
in the loop fragment 98–103, which is characterized by high
c© 2005 Biochemical Society
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Table 1 Data collection and refinement statistics
Data collection
Space group P21212
Unit cell
a (A˚) 43.3
b (A˚) 85.8
c (A˚) 64.9
α =β = γ (◦) 90
Resolution (A˚) 1.70
No. of observations (total/unique) 244 185/27 386
Multiplicity (overall/last shell) 3.7/2.9
Rmerge (%)* (overall/last shell) 7.3/12.0
Completeness (%) (overall/last shell) 98.6/93.0
Data refinement
Resolution range 20–1.7
R-factor†/R free (%) 19.9/22.1
No. of reflections (working/free) 25 568/1372
No. of water molecules 169
Average B-factor (A˚2)
Protein (main chain/side chain) 17.1/22.1
Iododiflunisal 32.1
Water 34.8
R.m.s. bonded Bs (A˚2) 1.448
R.m.s. deviations from standard geometry
R.m.s. bond length (A˚) 0.009
R.m.s. angle (◦) 1.280
Ramachandran plot
Most favoured (%) 93.0
Allowed (%) 7.0
* Rmerge =
∑
|I −〈I〉|/∑〈I〉, where I is the observed intensity and 〈I〉 is the average intensity
of multiple observations of symmetry-related positions.
† R-factor =∑||/F o| − |F c||/∑|F o|, where |F o| and |F c| are observed and calculated
structure factor amplitudes respectively.
thermal motion. On the other hand, when we compare the main
chain atom positions of the complexed and native (PDB accession
no. 1TTA [29]) protein structures, the r.m.s. deviation of 0.5 Å
indicates that the overall protein structure is conserved on ligand
binding. Small alterations occur in the hormone binding channel,
resulting from the binding of iododiflunisal, and will be analysed
in detail below.
Monomers A and B and their symmetry-related pair form a
cavity in the dimer interface that can accommodate simultane-
ously two T4 molecules. The two hormone-binding sites AA′ and
BB′ have similar topologies. They are funnel-shaped and mainly
hydrophobic, with hydrophilic contributions from residues Lys15
and Glu54 located at the entrance of the binding site. The initial
electron density map clearly indicated the position of the iodo-
diflunisal molecules, which occupy the binding sites available
in the protein for its natural ligand. Owing to the crystallographic
2-fold axis that runs along the channel, two symmetry-related
positions for iododiflunisal were observed in each binding site
(Figure 2). Therefore the occupancy of the two iododiflunisal
molecules was set initially to 0.5 and was refined as a free variable
to a final value of 0.35. Similar occupancy for the ligands was also
found in other X-ray structures of TTR in complex with binding
molecules. For example, in the models of TTR complexed with
flurbiprofen, dibenzofuran-4,6-dicarboxylic acid, o-trifluoro-
methylphenyl anthranilic acid and N-m-trifluoromethylphenyl-
phenoxazine-4,6-dicarboxylic acid, the ligand occupancies range
from 0.28 to 0.41 [12]. This deviation from the maximum value of
occupancy could be explained in light of the crystal structures
of TTR bound to its native ligand. Thus the crystal structure of
the TTR mutant TTR T119M (Thr119 → Met) bound to T4 [23]
was refined to a final occupancy value of 0.25 for the T4
Figure 2 Cα trace of TTR in complex with iododiflunisal
Monomers A (pink) and B (blue) form the crystallographic asymmetric unit. The 2-fold
symmetry-related monomers A′ and B′ are displayed in grey and green respectively. (A) Omit
F o–F c maps are contoured at 6σ over the hormone-binding site. The two strong density features
found in each binding site correspond to the position of the iodines of the two symmetry-related
iododiflunisal molecules. (B) Close view of the iododiflunisal binding site AA′ with omit maps
contoured at 6σ (orange) and 3σ (red).
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Figure 3 Stereo view of the interactions between the two symmetrically equivalent iododiflunisal molecules and TTR residues forming the AA′-binding site
Binding of iododiflunisal induces the rotation of the side chains of Ser117 and Ser117 ′ with the consequent formation of short hydrogen bonds between the hydroxy groups of Ser117 (A)–Ser117 (B)
and Ser117 (A′)–Ser117 (B′). Nζ of Lys15 is involved in weak hydrogen bond interactions with the CO2H and the OH groups of the iodine-substituted ring. For the hydroxy group, the interaction is
mediated by a water molecule. The iodine atom is involved in a series of hydrophobic contacts with the side chains of Thr106, Ala108, Thr119 and Val121.
atoms. In the present study, it has been described that a negative
co-operativity operates while the second molecule tries to reach
into the complex already formed by the entrance of a first T4
molecule. This effect can be measured in terms of the association
constants for binding of the first and the second T4 molecules,
which are in the region of 108 and 106 M−1 respectively [2]. It is
possible that this same influence also occurs for other ligands.
The position of the iodine atoms was unambiguously deter-
mined in the omit (Fo–Fc) electron density map contoured at 6σ ,
as indicated in Figure 2. In the final model, the symmetry-related
positions assume a ‘V’ form, with the iodine-substituted rings
placed away from the channel axis. A similar organization was
found in the TTR–diflunisal complex [30].
Protein–ligand interactions
The crystallographic structure of the TTR–T4 complex [31] al-
lowed a careful characterization of the hormone-binding sites,
which are composed of three symmetry-related hydrophobic small
depressions, termed halogen-binding pockets [32]. The innermost
pocket (P3) is formed by the side chains of Ala108, Leu110,
Ser117 and Thr119. It is essentially hydrophobic with nucleophilic
contributions from the Ser115 Oγ hydroxy and from the carbonyl
groups of Ser117, Thr118 and Ala108. The central pocket (P2) is
also hydrophobic and is composed of the methyl and methylene
groups of Leu110, Ala109, Lys15 and Leu17. The outmost pocket
(P1) is located between the side chains of Ala108, Thr106, Met13 and
Lys15. The Nζ of Lys15 is located close to the P1 pocket, allowing
potential electrostatic interactions with the ligands.
In the TTR–iododiflunisal complex, the fluorine-substituted
phenyl ring is positioned deep in the interior of the binding
cavity, with the two fluorine atoms accommodated in the P3 and
P3′ pockets (Figure 3). Those atoms are involved in extensive
hydrophobic interactions with Ala108, Leu110, Ser117, Thr118 and
Thr119 of monomers AA′ and BB′, which contribute to the overall
stability of the tetrameric structure.
The iodine-substituted phenyl ring is positioned close to the
entrance of the hormone-binding channel. The iodine atom estab-
lishes close hydrophobic interactions with side chains of residues
belonging to the two monomers that form each binding site: Leu17,
Table 2 Interatomic distances between the iodine substituent of iodo-
diflunisal and TTR at the two binding sites
Distance to the iodine substituent (A˚)
Residue Atom Binding sites: AA′/BB′
Leu17 Cδ1 3.84/3.81
Thr106 ′ O 4.04/3.93
Thr106 ′ Cγ 2 4.20/4.00
Ala108 ′ Cβ 3.24/3.36
Thr119 ′ O 3.98/4.00
Thr119 ′ Cγ 2 3.31/3.38
Val121 ′ N 4.06/3.96
Val121 ′ Cβ 3.90/4.08
Val121 ′ Cγ 2 2.69/3.29
Thr106 ′, Ala108 ′, Thr119 ′ and Val121 ′ (interatomic distances between
the iodine and protein atoms are listed in Table 2).
The phenolic hydroxy and carboxylate groups are involved
in hydrophilic interactions with Nζ of Lys15. A close inspection
shows slight differences between the positions of the ligand in the
two binding sites, namely in the position of the iodine-substituted
phenyl ring. In one of the binding sites, the CO2H group interacts
with lysine residues from both monomers, contributing further to
the stability of the tetrameric form of the protein. In the other
binding site, the carboxylate substituent forms a weak hydrogen
bond interaction with Nζ of Lys15 and the hydroxy group is
involved in a water-mediated polar interaction with the same Nζ .
Small differences between the positions of the ligand may be
associated with the expected negative co-operativity of ligand
binding, which was proved by isothermal titration calorimetry for
diflunisal and some diflunisal analogues [30].
Most of the studied small molecules affecting TTR tetramer
stability are two-ring biphenyl type structures. One of the rings
commonly presenting a carboxylic acid function is positioned in
the protein complex towards the outer part of the binding cavity
by forming electrostatic interactions with Nζ of Lys15. The second
aromatic ring is positioned in the inner part of the binding
channel and, since it is often substituted by halogen atoms (Cl
c© 2005 Biochemical Society
